Investors impressed by Sanofi’s estimate-topping results

25 April 2024
sanofi_large

Sanofi (Euronext: SAN) shares were up by nearly 4% during Thursday’s early afternoon trading in Paris following its results presentation.

The French pharma major had earlier presented its first-quarter 2024 financial results, revealing a 2% rise in sales to 10.46 billion euros ($11.22 billion), and business operating income for the period at 2.84 billion euros, a 15% decline compared to the same period a year ago.

Both figures beat a consensus of analyst predictions by more than 2%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical